This study has been transitioned to CTIS with ID 2024-514791-40-00 check the CTIS register for the current data. Based on results from a comparative review (Paoletti 2013), we hypothesize that if the toxicity profile and the PK parameters observed…
ID
Source
Brief title
Condition
- Leukaemias
- Miscellaneous and site unspecified neoplasms malignant and unspecified
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Trial End-points
1. The recommended phase II dose (RP2D) will be defined as the adult
recommended dose (adjusted for weight or BSA) if toxicity
and PK profiling are similar in children and in adults, or a higher dose,
providing it is below or equal to the maximum tolerated
dose (MTD).
2. The maximum tolerate dose (MTD) will be defined as the dose associated with
or closest to 25% of DLTs in cycle 1.
3. Dose Limiting Toxicities (DLT) will be defined using CTCAE v4.03.
4. Overall response rate (ORR); duration of response (DOR) will be defined as
the time period between the first documented
response (PR or CR) and the time of progression, according to RECIST v1.1, RANO
criteria for patients with HGG, INRC
criteria for patients with NB, etc.
5. Duration of response for patients free of progression at the cutoff date
will be censored at the last Imaging response scan date;
progression-free survival (PFS) will be defined as the time from treatment
initiation until the date of first documented progression
or death from any cause. Patients alive and free of progression at the cut-off
date will be censored at the last assessment date.
6. Adverse events according to the NCI CTCAE V4.03 in all cycles of treatment.
7. PK parameters, including but not limited to plasma concentration time
profiles, AUClast, AUCtau, Cmin, Cmax, Tmax, Clearance, Halflife
time.
8. To explore relationship between the molecular profile of the tumor samples,
circulating tumor DNA and tumor growth measured as modification of the sum of
the diameters of the target lesions over time.
Secondary outcome
NA
Background summary
The first molecular profiling protocols have been launched in Europe
(MOSCATO-01 (Geoerger 2014), MAPPYACTS, INFORM, iTHER,
SM-PAEDS, etc.) determining multiple actionable alterations in pediatric
recurrent cancers. Increasingly, stratified approaches are
being implemented to enrich clinical trials of molecularly targted agents and
possibly improve outcomes in specific populations i.e. a
molecularly enriched/predictive biomarker-driven approach. The diversity and
heterogeneity of the detected molecular alterations and
the low number of pediatric patients mandate an adapted, innovative trial
design for the attributed treatment options in order to satisfy the
current unmet medical need. This basket trial is designed to cover the
targeting of several survival pathways in oncogenesis that are currently not
adequately employed for pediatric patients in Europe.
Study objective
This study has been transitioned to CTIS with ID 2024-514791-40-00 check the CTIS register for the current data.
Based on results from a comparative review (Paoletti 2013), we hypothesize that
if the toxicity profile and the PK parameters observed in children treated at
the adult RP2D are similar to those in adults; escalating to the MTD is not
necessarily required, unless a dose-activity relationship has been documented
in adults. Therefore, for each agent or combination of agents being
investigated, there will be two co-primary objectives:
1. Phase I: To define or validate that the adult single agent RP2D of the
selected drug or combination of drugs is safe in children/adolescents and
equivalent to that seen in adults, in pediatric/adolescent patients with
malignancies which are recurrent or refractory to standard therapy.
2. Phase II: To determine the preliminary activity (as measured by tumor
response) of these agents in patients harboring specific molecular alterations
or tumor types that may be associated with the mechanism of action of these
drugs (i.e. molecularly enriched patient cohorts, where possible).
Secondary:
1. To characterize the toxicity profile of the agent(s) in pediatric/
adolescent patients.
2. To characterize single or multiple-dose PK of the agent(s).
3. To evaluate the progression free survival and incidence of longterm
responders (>6 months).
4. To evaluate whether the response rate is higher in the enriched population
as compared to the non-enriched population overall,
by targeted treatment and by arm.
Exploratory:
1. To explore, define and/or validate pharmacodynamic (Pd) biomarkers of target
inhibition, where possible.
2. To explore relationships between measures of tumor expression of the
molecular target(s), circulating tumor DNA and tumor growth.
3. To explore the expression of immunomarker (ARM J)
Study design
This is an international, multi-center, open-label, prospective, phase I/II
dose-validation study with a RP2D confirmation part, which is open to being
expanded to refine an efficacy assessment for each agent.
Each arm is driven separately with common procedures, quality control and
reporting.
For all patients, an extensive molecular analysis of their tumor tissue
performed prior to study entry will be requested that will serve to select the
most appropriate arm according to the algorithm provided below.
If no molecular alteration in the pathways selected for this trial are
identified, patients may still be enrolled into this study and assigned to a
particular treatment arm open for accrual, according to physician discretion,
if a strong scientific rationale exists to support the notion that the patient
may derive clinical benefit, and if the patient fulfills all other inclusion
and no exclusion criteria.
The study is designed to be amended subsequently with new treatment arms in
future for up to a maximum of 9 years.
Intervention
Arm A. Ribociclib + Topotecan and Temozolomide
ARM C. AZD1775 + Carboplatin
ARM D. Olaparib + Irinotecan
ARM I: Enasidenib
ARM J: Lirilumab + Nivolumab
Study burden and risks
NA
rue Edouard Vaillant 114
Villejuif 94805
FR
rue Edouard Vaillant 114
Villejuif 94805
FR
Listed location countries
Age
Inclusion criteria
1. Patients must be diagnosed with a haematologic or solid tumor malignancy
that has
progressed despite standard therapy, or for which no effective
standard therapy exists.
2. Age < 18 years at inclusion; patients 18 years and older may be
included after discussion with the sponsor if they have a pediatric
recurrent/refractory malignancy.
3. Patient must have had advanced molecular profiling ( i.e. WES/WGS +/-
RNAseq) of their
recurrent or refractory tumor i.e. at the time of disease
progression/relapse; exceptionally patients with advanced
molecular profiling at diagnosis may be allowed.
4. Evaluable or measurable disease as defined by standard imaging
criteria for the patient*s tumor type (RECIST v1.1, RANO criteria
for patients with HGG, INRC criteria for patients with NB,
Leukemia criteria, etc.).
5. Performance status: Karnofsky performance status (for patients
>12 years of age) or Lansky Play score (for patients <=12 years of
age) >= 70%. Patients who are unable to walk because of paralysis
or stable neurological disability, but who are up in a wheelchair,
will be considered ambulatory for the purpose of assessing the
performance score.
6. Life expectancy >= 3 months
7. Adequate organ function:
Hematologic criteria (Leukemia patients are excluded from
hematological criteria):
- Peripheral absolute neutrophil count (ANC) >= 1000/µL
(unsupported)
- Platelet count >= 100,000/µL (unsupported)
- Hemoglobin >= 8.0 g/dL (transfusion is allowed)
Cardiac function:
- Shortening fraction (SF) >29% (>35% for children < 3 years)
and left ventricular ejection fraction (LVEF) >=50% at baseline, as
determined by echocardiography (mandatory only for patients
who have received cardiotoxic therapy).
- Absence of QTc prolongation (QTc > 450 msec on baseline
ECG, using the Fridericia correction [QTcF formula]) or other
clinically significant ventricular or atrial arrhythmia.
Renal and hepatic function:
- Serum creatinine <= 1.5 x upper limit of normal (ULN) for age
- Total bilirubin <= 1.5 x ULN
- Alanine aminotransferase (ALT)/serum glutamic pyruvic
transaminase (SGPT) <= 2.5 x ULN; aspartate aminotransferase
(AST)/serum glutamic oxaloacetic transaminase/SGOT <= 2.5 x ULN
except in patients with documented tumor involvement of the liver
who must have AST/SGOT and ALT/SGPT <= 5 x ULN.
8. Able to comply with scheduled follow-up and with management of
toxicity.
9. Females of childbearing potential must have a negative serum or
urine pregnancy test within 72 hours prior to initiation of treatment.
Sexually active women of childbearing potential must agree to use acceptable
and appropriate contraception during the study and for at least 6 months after
the last study treatment administration. Sexually active males patients must
agree to use condom during the study and for at least 6 months (7 months for
arm J) after the last study treatment administration. Acceptable contraception
is listed in Appendix 12.
10. For all oral medications patients must be able to comfortably
swallow capsules (except for those for which an oral solution is
available); nasogastric or gastrostomy feeding tube administration
is allowed only if indicated.
11. Written informed consent from parents/legal representative,
patient, and age-appropriate assent before any study-specific
screening procedures are conducted according to local, regional
or national guidelines.
12. Patient affiliated to a social security regimen or beneficiary of the
same according to local requirements.
Exclusion criteria
1. Patients with symptomatic central nervous system (CNS)
metastases who are neurologically unstable or require increasing
doses of corticosteroids or local CNS-directed therapy to control
their CNS disease. Patients on stable doses of corticosteroids for
at least 7 days prior to receiving study drug may be included.
2. Impairment of gastrointestinal (GI) function or GI disease that
may significantly alter drug absorption of oral drugs (e.g.,
ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or
malabsorption syndrome).
3. Clinically significant, uncontrolled heart disease (including history
of any cardiac arrhythmias, e.g., ventricular, supraventricular,
nodal arrhythmias, or conduction abnormality, unstable ischemia, congestive
heart failure within 12 months of screening)
4. Active viral hepatitis or known human immunodeficiency virus
(HIV) infection or any other uncontrolled infection.
5. Presence of any >= CTCAE grade 2 treatment-related toxicity with
the exception of alopecia, ototoxicity or peripheral neuropathy.
6. Systemic anticancer therapy within 21 days of the first study dose
or 5 times its half-life, whichever is less.
7. Previous myeloablative therapy with autologous hematopoietic
stem cell rescue within 8 weeks of the first study drug dose
8. Allogeneic stem cell transplant within 3 months prior to the first
study drug dose. Patients receiving any agent to treat or prevent
graft-versus host disease (GVHD) post bone marrow transplant
are not eligible for this trial.
9. Radiotherapy (non-palliative) within 21 days prior to the first dose
of drug (or within 6 weeks for therapeutic doses of MIBG or
craniospinal irradiation).
10. Major surgery within 21 days of the first dose. Gastrostomy,
ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor
biopsy and insertion of central venous access devices are not
considered major surgery, but for these procedures, a 48 hour
interval must be maintained before the first dose of the
investigational drug is administered.
11. Currently taking medications with a known risk of prolonging the
QT interval or inducing Torsades de Pointes (Refer to Appendix
8).
12. Currently taking medications that are mainly metabolized by
CYP3A4/5, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug
transporters Pgp (MDR1), BCRP, OATP1B1, OATP1B3, OCT1
and OCT2 and have a low therapeutic index that cannot be
discontinued at least 7 days or 5 x reported elimination half-life
prior to start of treatment with any of the investigational drugs and
for the duration of the study (Refer to Appendix 9).
13. Known hypersensitivity to any study drug or component of the
formulation.
14. Pregnant or nursing (lactating) females.
15. Vaccinated with live, attenuated vaccines within 4 weeks of the
first dose of study drug.
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
EU-CTR | CTIS2024-514791-40-00 |
EudraCT | EUCTR2016-000133-40-NL |
ClinicalTrials.gov | NCT02813135 |
CCMO | NL60586.078.17 |